Evidence map›Paper›PMID 32295782›Full record

ArticleCancer research2020

Loss of BAP1 Leads to More YAPing in Pancreatic Cancer.

Rolf A Brekken

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Rolf A BrekkenHamon Center for Therapeutic Oncology Research, Division of Surgical Oncology, Department of Surgery, Department of Pharmacology, UT Southwestern, Dallas, Texas. rolf.brekken@utsouthwestern.edu.
Southwestern Medical Center · US

Funding

Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, RONGFU · 2016 to 2020
$9.3M
Exploitation of RAS signaling to develop therapy and early detection strategies for PDAR01CA192381 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BREKKEN, ROLF A, WILKIE, THOMAS M · 2015 to 2019
$2.2M
NCI NIH HHS R01 CA192381NCI NIH HHS U54 CA210181
6 · The paper itself

Abstract

Pancreatic cancer is increasing in incidence and is expected to be the second leading cause of cancer-related mortality by the year 2030. Understanding molecular pathways that contribute to pancreatic cancer initiation and progression provides the opportunity to uncover potential molecular vulnerabilities that can be exploited therapeutically. In this issue of

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHippo Signaling PathwayHumansProtein Serine-Threonine KinasesSignal TransductionTumor Suppressor ProteinsUbiquitin ThiolesteraseBAP1 protein, humanProtein Serine-Threonine KinasesTumor Suppressor ProteinsUbiquitin Thiolesterase

Identifiers

PMID32295782
OpenAlexW3016465374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.